Key result
Gain of chromosome 1q was associated with adverse overall survival in patients with Ewing tumours, doubling the relative hazard of failure.
Why the study?
Does the presence of specific chromosomal aberrations (gain of 1q, loss of 16q) predict adverse survival outcomes in patients with Ewing tumours?
Cohort (n=134)
Yes
Does the presence of specific chromosomal aberrations (gain of 1q, loss of 16q) predict adverse survival outcomes in patients with Ewing tumours?
Assessment of 1q and 16q copy numbers in Ewing tumours provides important prognostic information, identifying patients at higher risk of adverse outcomes.
Answers are grounded in this paper and cite their sources.
1q gain supports refined prognostication in Ewing tumours; hypothesis-generating and requires prospective validation before guiding therapy.
Although greater than 50% of Ewing tumours contain non-random cytogenetic aberrations in addition to the pathognomonic 22q12 rearrangements, little is known about their prognostic significance. To address this question, tumour samples from 134 Ewing tumour patients were analysed using a combination of classical cytogenetics, comparative genomic and fluorescence in situ hybridisation. The evaluation of the compiled data revealed that gain of chromosome 8 occurred in 52% of Ewing tumours but was not a predictive factor for outcome. Gain of 1q was associated with adverse overall survival and event-free survival in all patients, irrespective of whether the tumour was localised or disseminated (overall survival: P=0.002 and P=0.029; event-free survival: P=0.018 and P=0.010). Loss of 16q was a significant predictive factor for adverse overall survival in all patients (P=0.008) and was associated with disseminated disease at diagnosis (P=0.039). Gain of chromosome 12 was associated with adverse event-free survival (P=0.009) in patients with localised disease. These results indicate that in addition to a 22q12 rearrangement confirmation in Ewing tumours it is important to assess the copy number of 1q and 16q to identify patients with a higher probability of adverse outcome.
No takes yet. Share an insight, caveat, or question.
Hattinger et al. (2002) conducted a cohort in Ewing tumours (n=134). Gain of chromosome 1q vs. No gain of chromosome 1q was evaluated on 5-year overall survival (RHR 2, p=0.046). Gain of chromosome 1q was associated with adverse overall survival in patients with Ewing tumours, doubling the relative hazard of failure.
Synapse has enriched 10 related papers. Consider them for comparative context: